Recent Advances in Drug Delivery for the Treatment of Colorectal Cancer

A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".

Deadline for manuscript submissions: 10 October 2024 | Viewed by 229

Special Issue Editor


E-Mail Website
Guest Editor
Department of Cancer Biology, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, USA
Interests: fluoropyrimidine; colorectal cancer; thymidylate synthase; DNA topoisomerase 1; DNA repair
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Colorectal cancer (CRC) is the second-leading cause of cancer-related mortality in men and women combined. Chemotherapy in the adjuvant setting provides a survival benefit by reducing the incidence of recurrent disease which frequently involves metastatic progression, often to the liver but also to the lungs and other sites. Advancements in combination chemotherapy for metastatic CRC (mCRC) have significantly improved the overall survival rates; however, treatment is rarely curative, and new approaches are needed.

This Special Issue aims to illuminate the most promising therapeutic approaches for improving outcomes in CRC with an emphasis on original research articles and comprehensive reviews highlighting the most recent advancements. Articles covering any of the subject areas relevant to the scope of Pharmaceutics are welcome, including advancements in nanomedicine and formulation that are relevant to the improved treatment of CRC. New delivery and controlled-release systems for drugs, vaccines, and biopharmaceuticals targeting improved CRC treatment will be highlighted in this Special Issue, as well as advancements in pharmaceutical formulation, pharmacogenomics, and pharmacogenetics. Research contributions highlighting advancements in extending the scope of immunotherapy in CRC treatment are of particular interest.

I am pleased to invite you to contribute to “Recent Advances in Drug Delivery for the Treatment of Colorectal Cancer” by sending your most cutting-edge research accomplishments for inclusion in this Special Issue. I look forward to receiving your contributions.

Prof. Dr. William H. Gmeiner
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • colorectal cancer
  • targeted therapy
  • drug delivery
  • drug design
  • immunotherapy
  • biopharmaceuticals
  • pharmacogenomics

Published Papers

This special issue is now open for submission.
Back to TopTop